Vivos Therapeutics Inc Stock

$2.70

11.76% yesterday

Nasdaq, Sep 27, 10:15 pm CET

ISIN

US92859E1082

Symbol

VVOS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Overview Dividends Analysts Charts News Strategies

Vivos Therapeutics Inc Stock price

$2.70

-222.05 98.80% 5Y

Nasdaq, Closing price Fri, Sep 27 2024

-0.36 11.76%

ISIN

US92859E1082

Symbol

VVOS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Key metrics

Market capitalization	$14.58m
Enterprise Value	$9.44m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	0.67
P/S ratio (TTM) P/S ratio	1.04
P/B ratio (TTM) P/B ratio	1.64
Revenue growth (TTM) Revenue growth	-9.23%
Revenue (TTM) Revenue	$14.02m
EBIT (operating result TTM) EBIT	$-13.49m
Free Cash Flow (TTM) Free Cash Flow	$-11.64m
Cash position	$6.90m
EPS (TTM) EPS	$-6.30
P/E forward	negative
P/S forward	0.90
EV/Sales forward	0.58
Short interest	2.29%

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Get Started for Free Today

Vivos Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

2 Analysts have issued a Vivos Therapeutics Inc forecast:

2x Buy

100%

More details on Analyst Estimates Including Price Targets

2 Analysts have issued a Vivos Therapeutics Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Vivos Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	14 14	9% 9% 100%
- Direct Costs	6.19 6.19	9% 9% 44%
Gross Profit	7.83 7.83	9% 9% 56%
- Selling and Administrative Expenses	21 21	28% 28% 148%
- Research and Development Expense	- -	- -
EBITDA	-13 -13	37% 37% -92%
- Depreciation and Amortization	0.59 0.59	12% 12% 4%
EBIT (Operating Income) EBIT	-13 -13	36% 36% -96%
Net Profit	-12 -12	36% 36% -86%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Vivos Therapeutics Inc Stock News

Positive

Proactive Investors

●

8 days ago

Vivos Therapeutics raises $4.3 from institutional investors

Vivos Therapeutics (NASDAQ:VVOS) announced that it has entered into definitive purchase agreements with institutional investors to raise proceeds of $4.3 million through the issuance and sale of an aggregate of 1,363,812 shares at $3.15 each. The company said that no stock purchase warrants are being issued in this at-the-market offering.

Positive

Proactive Investors

●

9 days ago

Vivos Therapeutics' oral device approved by FDA for pediatric sleep apnea treatment

Vivos Therapeutics (NASDAQ:VVOS) announced that it has received US Food and Drug Administration (FDA) approval to treat moderate to severe obstructive sleep apnea (OSA) in children aged 6 to 17 using its proprietary oral medical device. This non-invasive, orthodontic-based solution offers an alternative to traditional treatments like adenotonsillectomy, which may not always be effective long-term.

Neutral

GlobeNewsWire

●

10 days ago

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model

More Vivos Therapeutics Inc News

Company Profile

Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Highlands Ranch, CO.

Head office	United States
CEO	R. Huntsman
Employees	114
Founded	2016
Website	www.vivos.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now